Roth Capital Initiates Spark Therapeutics At Buy

Analysts at Roth Capital initiated coverage on

with a Buy rating. The target price for Spark Therapeutics is set to $71. Spark Therapeutics' shares rose 0.87% to $46.40 in after-hours trading.